Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ehf2.12952 http://scihub22266oqcxt.onion/10.1002/ehf2.12952 33121220!7524232!33121220     free     free     free       ESC+Heart+Fail 2020 ; 7 (5): 3119-3123 Nephropedia Template TP {{tp|p=33121220|t=2020. Relating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID-19 |pdf=|usr=}}{{33121220}} gab.com Text Relating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID-19 JO: ESC Heart Fail http://www.kidney.de/pget.php?&tw=1&pmid=33121220 #FOAvip The present Perspective examined the latest evidence on the association between the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and the incidence/mortality of coronavirus disease 2019 (COVID-19). Our critical appraisal from existing literature does not support discontinuation of ACEIs/ARBs in clinical practice as there is absence of solid evidence. However, we do recommend future research perspective in formulation and implementation of practice-changing guidelines. Twit Text FOAVip Relating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID-19 ????ESC Heart Fail http://www.kidney.de/pget.php?&tw=1&pmid=33121220 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33121220 #FOAvip English Wikipedia <ref>{{Cite pmid|33121220}}</ref> Relating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID-19 #MMPMID33121220 Wong MCS; Wong S; Huang J; Yan B ESC Heart Fail 2020[Oct]; 7 (5): 3119-3123 PMID33121220show ga The present Perspective examined the latest evidence on the association between the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and the incidence/mortality of coronavirus disease 2019 (COVID-19). Our critical appraisal from existing literature does not support discontinuation of ACEIs/ARBs in clinical practice as there is absence of solid evidence. However, we do recommend future research perspective in formulation and implementation of practice-changing guidelines. |Adult[MESH] |Aged[MESH] |Angiotensin Receptor Antagonists/*adverse effects/therapeutic use[MESH] |Angiotensin-Converting Enzyme Inhibitors/*adverse effects/therapeutic use[MESH] |COVID-19[MESH] |Cause of Death[MESH] |Coronavirus Infections/*drug therapy/mortality[MESH] |Female[MESH] |Hospital Mortality/trends[MESH] |Humans[MESH] |Incidence[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics/*statistics & numerical data[MESH] |Pneumonia, Viral/*drug therapy/mortality[MESH] |Prognosis[MESH] |Risk Assessment[MESH] |Severe Acute Respiratory Syndrome/drug therapy/*mortality[MESH]Relating angiotensin-converting enzyme inhibitors or angiotensin recep(epmc).pdf DeepDyve Pubget Overpricing